← All trials
NCT05470803
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Aug 31, 2023
- First posted
- Jul 22, 2022
- Last posted
- Jul 22, 2022
- Enrollment
- 360
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- D'Or Institute for Research and EducationLead sponsor
- University of OxfordCollaborator
- Bill and Melinda Gates FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.